Table 5.

Practice patterns of antiplatelets and anticoagulants among patients with concomitant HF and CAD

Country/Study	Study design	Population	Observation period	Antiplatelet use, % patients			Anticoagulant use, % patients
				Aspirin	Clopidogrel	Other	Warfarin
Australia/Krum et al., 2006 38	Multicentre	116 patients with MI and HF	2004–2005	84	55	NR	13
Canada/Ezekowitz et al., 2004 39	Prospective cohort	6427 patients with HF and angiographically proven CAD	NR	73	NR	25a	29
US/Newby et al., 2006 40	Retrospective registry (database)	8914 patients with CAD and HF	1995–2002	75.3	NR	6.1b	13
International‐STICH trial (22 countries)/Velazquez et al., 201129	Multicenter, nonblinded, randomized	1212 patients with CAD suitable for revascularization and LVEF ≤ 0.35	July 2002‐May 2007	84	13–16	NR	20–21

CAD, coronary artery disease; HF, heart failure; LVEF, left ventricular ejection fraction; MI, myocardial infarction; NR, not reported; STICH, Surgical Treatment for Ischemic Heart Failure; US, United States.

^aAny thienopyridine.

^bNonaspirin antiplatelet.